We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byRamon Schooley
Modified about 1 year ago
Leadership. Knowledge. Community. Guideline Pearls Canadian Cardiovascular Society Antiplatelet Guidelines
Objective To interpret a quick summary of the key “takeaways” from the Canadian Cardiovascular Society Antiplatelet Guidelines. © 2011 - TIGC
Guideline Pearls Do’s and Don’ts Primary prevention DODON’T Consider ASA only where there is clear evidence of high risk. Asymptomatic carotid stenosis Asymptomatic coronary atherosclerosis Reduced ABI Use antiplatelet therapy for primary prevention. © 2011 - TIGC
Guideline Pearls Do’s and Don’ts Cerebrovascular disease Provide lifetime antiplatelet Rx to all patients post ischemic stroke or TIA. Consider DAPT with ASA + Clopidogrel in patients with high risk TIA or minor stroke for 30 days. Use DAPT with ASA + Clopidogrel for long term secondary stroke prevention. © 2011 - TIGC DODON’T
Guideline Pearls Do’s and Don’ts ACS/PCI Provide lifetime antiplatelet Rx to all patients post ACS with or without PCI. Provide DAPT with ASA + P2Y12 inhibitor to all ACS patients. Know the type of stent your patient has inserted. Consider DAPT beyond 1 year in patients with high risk of thrombosis and low risk of bleeding. Use doses of ASA above 75 – 162 mg. Discontinue DAPT prior to 1 yr without a very good reason. EVER discontinue DAPT in a patient with a Drug Eluting Stent prior to 1 yr, EVER. DODON’T © 2011 - TIGC
Guideline Pearls Do’s and Don’t’s Management of patients post ACS who require surgery, diagnostic or dental procedures Delay such procedures in patients taking DAPT. Stop clopidogrel for 7-10 days prior if it can be done so safely. Stop ASA for 7 – 10 days for bleeding high risk surgical procedures. Discontinue DAPT prior to 1 year in patients with Drug Eluting Stents EVER. Stop ASA for minor procedures including: Arthrocentesis Dental procedures Cataract surgery Skin excisions © 2011 - TIGC DODON’T
Minor bleeding management Stop antiplatelet therapy for: Eccymosis Petechia Subconjunctival hemorrhage Epistaxis Dental / gingival bleeding tranexamic acid mouthwash If persistent check: Complete blood count INR and activated Partial thromboplastin time (aPTT) Guideline Pearls Do’s and Don’t’s DODON’T © 2011 - TIGC
Drug interactions Use PPI’s that inhibit CYP2C19 in patients taking clopidogrel or prasugrel. Use NSAIDs or Coxibs in patients at increased risk of vascular events. Use Coxibs over traditional NSAIDs in patients taking ASA for CV prevention but only if absolutely necessary. Guideline Pearls Do’s and Don’t’s DODON’T © 2011 - TIGC
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines PERIOPERATIVE MANAGEMENT OF ANTIPLATELET THERAPY Working Group:
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines MANAGEMENT OF ANTIPLATELET THERAPY IN ASSOCIATION WITH MINOR.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
RECOMMENDATIONS Canadian Cardiovascular Society Anti Platelet Guideline 2010 Alan D. Bell, MD, CCFP; Raymond Cartier, MD; Wee Shian Chan, MD, FRCP; James.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE.
Leadership. Knowledge. Community. Antiplatelet Therapy for the Secondary Prevention of Cerebrovascular Disease Working Group: Ashfaq Shuaib, MD, FRCP;
Leadership. Knowledge. Community. Introduction Canadian Cardiovascular Society Antiplatelet Guidelines.
Leadership. Knowledge. Community. Antiplatelet Therapy for the Primary Prevention of Vascular Events Working Group: Alan D. Bell, MD, CCFP and James D.
수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
Leadership. Knowledge. Community. Antiplatelet Therapy for Secondary Prevention Beyond One Year Following ACS or PCI Working Group: Anil Gupta MD, FRCPC,
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines Antiplatelet Therapy for Vascular Prevention in Patients with.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Medications that impact bleeding By Nino Lalaiants Inesa Legrian NYCCT 2012.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
The Primary and Secondary Prevention of Cardiovascular Disease Per Olav Vandvik, MD, PhD A. Michael Lincoff, MD Joel M. Gore, MD David Gutterman, MD, FCCP.
Post oral surgery bleeding for adult patients receiving antithrombotic therapy.
LSU Journal Club Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE trial: Clopidogrel in High-risk patients with Acute.
North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.
Secondary prevention after a TIA or ischemic stroke.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
Antiplatelet therapy in CAD MINILECTURE. Objectives Indications for Antiplatelet Therapy in patients with CAD and ACS Antiplatelet Therapy in the role.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):
Clopidogrel Audit Vikas Jasoria December What is it? Clopidogrel is a thienopyridine antiplatelet drug which reduces platelet aggregation by inhibiting.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines INTERACTION BETWEEN CLOPIDROGEL AND PROTON PUMP INHIBITORS Working.
Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
Leadership. Knowledge. Community. Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome Working Group: Jean-François.
Biondi-Zoccai: Dual antiplatelet Rx durationwww.metcardio.org ACUTE CORONARY SYNDROMES: why avoiding discontinuation of dual antiplatelet therapy Giuseppe.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Sticky Issues with Antiplatelet Therapy Goal Have an understanding, based on a review of current literature, on how to manage patients on antiplatelet.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Practical Management of Anticoagulation in Patients.
CV Update – Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet – 27/01/09 Dr Ameet Bakhai, FRCP – Cardiologist, Clinical Trials, Health.
TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel TRITON-TIMI 38 TRITON-TIMI 38 Elliott M. Antman, MD.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
Giovanni Maria Santoro S. C. Cardiologia Ospedale San Giovanni di Dio Firenze Gestione del paziente con stent coronarico. Il mantenimento della doppia.
1 HOT LINE PRESENTATION World Congress of Cardiology 2006 Barcelona, Spain September 5, 2006 Warfarin Antiplatelet Vascular Evaluation PAD Patients.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.
Medical Prevention of Stroke November 17, 2000 Ash Singhal University of Toronto.
Regulatory History of Aspirin Cardiovascular and Renal Drugs Advisory Committee Meeting Michelle M. Jackson, Ph.D. Division of Over-The-Counter Drug Products.
Antithrombotic Therapy in Peripheral Artery Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
© Continuing Medical Implementation ® …...bridging the care gap Geriovascular Prevention Optimizing Prevention of Cardiovascular Disease in the Elderly.
Glycoprotein IIb/IIIa inhibitors and bivalirudin: under utilised? Azfar Zaman Freeman Hospital Newcastle-upon-Tyne.
Side Effects Nitroglycerin Pills Plavix Buy Cheap Plavix plavix malaysia price clopidogrel bisulfate assistance program cva on plavix coplavix medication.
Plavix Dose Buy Plavix Online plavix and root canals post cabg and plavix can you get rebound headaches from plavix plavix effect with surgery do i need.
© 2017 SlidePlayer.com Inc. All rights reserved.